Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients
Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients
| dc.contributor.author | Schluckebier, Luciene | |
| dc.contributor.author | Caetano, Rosangela | |
| dc.contributor.author | Garay, Osvaldo Ulises | |
| dc.contributor.author | Montenegro, Giuliana T. | |
| dc.contributor.author | Custodio, Marcelo | |
| dc.contributor.author | Aran, Veronica | |
| dc.contributor.author | Ferreira, Carlos Gil | |
| dc.date.accessioned | 2024-10-08T17:44:53Z | |
| dc.date.available | 2024-10-08T17:44:53Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Background: The treatment of choice for advanced non–small cell lung cancer is selected according to the presence of specific alterations. Patients should undergo molecular testing for relevant modifications and the mutational status of EGFR and translocation of ALK and ROS1 are commonly tested to offer the best intervention. In addition, the tests costs should also be taken in consideration. Therefore, this work was performed in order to evaluate the cost-effectiveness of a unique exam using NGS (next generation sequencing) versus other routinely used tests which involve RT-PCR and FISH. Methods: The target population was NSCLC, adenocarcinoma, and candidates to first-line therapy. Two strategies were undertaken, strategy 1 corresponded to sequential tests with EGFR RT-PCR, then FISH for ALK and ROS1. Strategy 2 differed from 1 in that ALK and ROS1 translocation testing were performed simultaneously by FISH. Strategy 3 considered single test next-generation sequencing, a platform that includes EGFR, ALK and ROS1 genes. A decision tree analysis was used to model genetic testing options. From the test results, a microsimulation model was nested to estimate survival outcomes and costs of therapeutic options. Results: The use of NGS added 24% extra true cases as well as extra costs attributed to the molecular testing. The ICER comparing NGS with sequential tests was US$ 3479.11/correct case detected. The NGS improved a slight gain in life years and QALYs. Conclusion: Our results indicated that, although precise, the molecular diagnosis by NGS of patients with advanced stage NSCLC adenocarcinoma histology was not cost-effective in terms of quality-adjusted life years from the perspective of the Brazilian supplementary health system. | |
| dc.identifier.citation | Schluckebier L, Caetano R, Garay OU, Montenegro GT, Custodio M, Aran V, Gil Ferreira C. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. BMC Cancer. 2020 Sep 14;20(1):875. doi: 10.1186/s12885-020-07240-2. | |
| dc.identifier.other | DOI: 10.1186/s12885-020-07240-2. | |
| dc.identifier.uri | https://dspace.inc.saude.gov.br/handle/123456789/479 | |
| dc.language.iso | en | |
| dc.publisher | BMC Cancer | |
| dc.subject | Lung cancer | en |
| dc.subject | NGS | en |
| dc.subject | NSCLC | en |
| dc.subject | Diagnostic methods | en |
| dc.subject | Health economics | en |
| dc.subject | EGFR | en |
| dc.subject | ALK | en |
| dc.subject | ROS1 | en |
| dc.title | Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients | |
| dc.type | Article |